Foghorn Therapeutics INC 8-K filings

Foghorn Therapeutics is progressing its pipeline of precision therapeutics, with key data readouts and clinical initiations expected through 2026.

Foghorn Therapeutics has entered into an underwriting agreement for a public offering of common stock and pre-funded warrants to raise capital.

Foghorn Therapeutics is progressing its pipeline of precision therapeutics, with key data readouts and clinical initiations expected in the near term.

Foghorn Therapeutics' investor presentation details their progress in developing precision medicines targeting chromatin biology, including updates on clinical trials and strategic partnerships.

Foghorn Therapeutics announced its first quarter 2024 financial results and provided a corporate update, highlighting progress in its clinical programs and a strong cash position.

Foghorn Therapeutics has appointed Kristian Humer as its new Chief Financial Officer, effective immediately, bringing extensive financial and life science experience to the role.

Foghorn Therapeutics presented encouraging preclinical data for its BRM selective inhibitor, FHD-909, and selective CBP and EP300 degrader programs at the 2024 AACR Annual Meeting.

Foghorn Therapeutics reported its 2023 financial results, highlighted clinical progress, and provided a strategic outlook, including a cash runway into the first half of 2026.

Foghorn Therapeutics announces that Eli Lilly has selected FHD-909, a first-in-class oral BRM selective inhibitor, for clinical development, with an IND filing planned for the second quarter of 2024.

Foghorn Therapeutics has appointed Stephen J. DiPalma as interim Chief Financial Officer, effective immediately, while the search for a permanent CFO continues.